Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost- effectiveness analysis

Clinical Therapeutics

Volumn 22, Issue 3, 2000, Pages 362-370

  Shah, Hemal ^a   Gondek, Kathleen ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Aspirin; Cerebral infarction; Cerebrovascular disease; Costs and cost analysis; Dipyridamole; Model (economic)

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; HUMAN; MEDICARE; MONOTHERAPY; PROPHYLAXIS; RECURRENT DISEASE; SUSTAINED RELEASE PREPARATION;

EID: 0034003929     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80041-7     Document Type: Article

References (16)

1. 1. American Heart Association. 1999 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 1998.
2. 2. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study. Stroke. 1998;29:415-421.
3. 3. Burn J, Dennis M, Bamford J, et al. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke. 1994;25:333-337.
4. 4. Johnson ES, Lanes SF, Wentworth CE III, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med. 1999;159:1248-1253.
5. 5. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996:143:1-13.
6. 6. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
7. 7. Albers GW, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 1998;114(Suppl): 683S-698S.
8. 8. Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52:259-271.
9. 9. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
10. 10. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 1998;50:883-890.
11. 11. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke. 1994;25:1149-1156.
12. 12. Scott G, Scott HM. Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis. Pharmacoeconomics. 1997;6:667-674.
13. 13. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: A Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999;30:338-349.
14. 14. Cardinale V. Drug Topics®, Red Book®. Montvale, NJ: Medical Economics Company, Inc; 1999.
15. 15. Holloway RG, Benesch CG, Rahilly CR, Courtright CE. A systematic review of cost-effectiveness research of stroke evaluation and treatment. Stroke. 1999;30:1340-1349.
16. 16. Schulman KA. Pharmacoeconomics and clinical practice: A physician's view. In: Bootman LJ, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. Cincinnati, Ohio: Harvey Whitney Books Company; 1996:259-275.